You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
醫藥股榮辱互見 新華製藥續升逾8% 騰盛博藥及三葉草續跌逾7%至11%
醫藥及在線醫療股今天榮辱互見,疫苗股三葉草生物-B(02197.HK)沽壓最大,股價失守上周配股價3.95元,最低見3.5元,現報3.57元,挫近11%,成交增至5,816萬股。 騰盛博藥-B(02137.HK)續跌7.7%報8.38元;開拓藥業-B(09939.HK)、復星醫藥(02196.HK)及康希諾生物(06185.HK)也倒跌逾2%-4%,康希諾生物沽壓最大報87.35元,跌4.3%。國藥控股(01099.HK)反覆高見21.35元創逾一年高遇壓,最低見20.1元,現報20.45元,反覆回吐1.9%。 平安好醫生(01833.HK)盤中曾高見34.2元創逾52周新高遇阻,其後掉頭一度低見28.2元,現報29.35元,倒跌近6%。阿里健康(00241.HK)曾高見9.63元無以為繼,掉頭低見8.69元,現報8.83元,續跌3.6%。 藍籌藥明生物(02269.HK)續跌逾1%曾低見50.45元;藥明康德(02359.HK)高開報79.05元欠承接,現報75.5元,續跌近4%。藍籌石藥(01093.HK)及翰森製藥(03692.HK)跌逾3.5%-5%,翰森製藥沽壓最大,股價跌破20天、250天線及10天線(14.75-15.05元),最低見14.28元,現報14.42元,續跌5.6%。 康龍化成(03759.HK)及泰格醫藥(03347.HK)反覆跌約1.5%至3%。 然而,新華製藥(000719.HK)屢破頂,最高見17元,現報14.2元,續升8.4%。基石藥業(02616.HK)反覆回升5.6%曾高見4.8元;歌禮製藥(01672.HK)高見4.15元,現報3.75元,續升4.7%。康方生物(09926.HK)反覆回升3.6%報41.6元。信達生物(1801.HK)反覆回升逾1.5%曾高見33.5元。藥明巨諾(02126.HK)反覆回升1.8%報5.03元。百濟神州(06160.HK)回升2.8%曾高見124.7元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account